Pending AI has developed a world-first pharmaceutical discovery platform, leveraging scalable artificial intelligence and quantum mechanics to usher in a new paradigm of best-in-class and first-in-class medicinal innovation. Our approaches to computational drug discovery can: 1) model drugs, disease proteins and their interactions with a level of precision unachievable with existing methods, and 2) dramatically expand discovery possibilities through generating trillion-scale drug libraries and unlocking druggability of interesting disease targets.

Why work with us

Partnerships with large academic publishing houses (e.g. Elsevier) to access world-class, unique datasets means artificial intelligence models demonstrate superiority in overall performance. These are not available to most other companies.

Application of quantum mechanical calculations to entire protein structures (restricted to much smaller-scale systems today), facilitating the druggability of well-established but traditionally difficult-to-drug targets. This capability has not been replicated by another company.

Pending AI team has a combination of unique yet synergistic skill sets, evidenced by the impressive scientific track records of: Dr. Mark Waller, Dr. Uli Fechner, and Dr. Holger Kruse, each of which have published several seminal papers in the field, collectively attracting several thousand citations.